Medicines for Cancer: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies covers most known anti-cancer therapeutics. Cancer is the second leading cause of death worldwide, with its various forms resulting in nearly one out of every six mortalities each year. This book describes all US FDA-approved drugs (up to 2021), such as small molecules, peptides, monoclonal antibodies, whole antibodies, gene therapy, antibody-drug conjugates, cell therapy, and immunotherapies, along with information on their generic and brand names, medical uses, details dosage, mechanisms of actions, pharmacokinetics and side effects. Chemical structures of small molecules, small peptides, antibody-drug conjugates are also provided.
This book is ideal for medicinal chemists, oncologists, and pharmacologists, but it will also be indispensable for professional researchers, whether they are working in the clinic or the pharmaceutical industry.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Medical advice disclaimer - p. v 6. About the author - p. xvii 7. Preface - p. xix 8. Common abbreviations and acronyms - p. xxi 9. Chapter 1. Drug nomenclature - p. 1 10. Chapter 2. Chemotherapy - p. 7 11. 2.1. Alkylating antineoplastic agents - p. 7 12. 2.2. Nitrosoureas - p. 7 13. 2.3. Antimetabolites - p. 7 14. 2.4. Antitumor antibiotics - p. 8 15. 2.5. Topoisomerase inhibitors - p. 8 16. 2.6. Mitotic inhibitors (antimicrotubule agents) - p. 8 17. 2.7. Corticosteroids - p. 9 18. 2.8. Other chemotherapy drugs - p. 9 19. 2.9. US FDA-approved current chemotherapy agents - p. 9 20. 2.10. Albumin-bound paclitaxel - p. 9 21. 2.11. Amifostine - p. 11 22. 2.12. Arsenic trioxide - p. 12 23. 2.13. Asparaginase Erwinia chrysanthemi - p. 14 24. 2.14. Azacitidine - p. 15 25. 2.15. Bendamustine - p. 16 26. 2.16. Bleomycin - p. 18 27. 2.17. Busulfan - p. 19 28. 2.18. Cabazitaxel - p. 21 29. 2.19. Calaspargase pegol-mknl - p. 23 30. 2.20. Capecitabine - p. 24 31. 2.21. Carboplatin - p. 26 32. 2.22. Carmustine - p. 27 33. 2.23. Chlorambucil - p. 28 34. 2.24. Cisplatin - p. 30 35. 2.25. Cladribine - p. 31 36. 2.26. Clofarabine - p. 33 37. 2.27. Cyclophosphamide - p. 35 38. 2.28. Cytarabine - p. 36 39. 2.29. Dacarbazine - p. 38 40. 2.30. Dactinomycin - p. 39 41. 2.31. Daunorubicin - p. 41 42. 2.32. Decitabine - p. 42 43. 2.33. Dexamethasone - p. 44 44. 2.34. Docetaxel - p. 45 45. 2.35. Doxorubicin - p. 47 46. 2.36. Doxorubicin liposome - p. 49 47. 2.37. Epirubicin - p. 50 48. 2.38. Eribulin mesylate - p. 52 49. 2.39. Etoposide - p. 53 50. 2.40. Fludarabine - p. 55 51. 2.41. 5-Fluorouracil - p. 56 52. 2.42. Gemcitabine - p. 58 53. 2.43. Hydroxyurea - p. 61 54. 2.44. Idarubicin - p. 62 55. 2.45. Ifosfamide - p. 64 56. 2.46. Irinotecan - p. 66 57. 2.47. Ixabepilone - p. 68 58. 2.48. Lomustine - p. 69 59. 2.49. Lurbinectedin - p. 70 60. 2.50. Lutetium Lu 177-dotatate - p. 72 61. 2.51. Mechlorethamine - p. 73 62. 2.52. Melphalan - p. 74 63. 2.53. Mercaptopurine - p. 76 64. 2.54. Methotrexate - p. 77 65. 2.55. Mitomycin-C - p. 79 66. 2.56. Mitoxantrone - p. 80 67. 2.57. Nelarabine - p. 82 68. 2.58. Oxaliplatin - p. 83 69. 2.59. Paclitaxel - p. 85 70. 2.60. Pemetrexed - p. 87 71. 2.61. Pralatrexate - p. 89 72. 2.62. Procarbazine - p. 90 73. 2.63. Radium 223 dichloride - p. 92 74. 2.64. Temozolomide - p. 93 75. 2.65. Thioguanine - p. 94 76. 2.66. Thiotepa - p. 96 77. 2.67. Topotecan - p. 97 78. 2.68. Trabectedin - p. 99 79. 2.69. Valrubicin - p. 100 80. 2.70. Vinblastine - p. 102 81. 2.71. Vincristine - p. 103 82. 2.72. Vinorelbine - p. 105 83. Chapter 3. Hormonal therapy - p. 161 84. Chapter 4. Targeted therapy: small molecules - p. 205 85. 4.1. Small molecules - p. 205 86. 4.2. Small molecules as targeted therapy - p. 205 87. 4.3. Abemaciclib - p. 205 88. 4.4. Acalabrutinib - p. 207 89. 4.5. Afatinib - p. 208 90. 4.6. Alectinib - p. 210 91. 4.7. Alpelisib - p. 211 92. 4.8. Avapritinib - p. 212 93. 4.9. Axitinib - p. 214 94. 4.10. Belinostat - p. 216 95. 4.11. Bexarotene - p. 217 96. 4.12. Binimetinib - p. 218 97. 4.13. Bortezomib - p. 220 98. 4.14. Bosutinib - p. 222 99. 4.15. Brigatinib - p. 223 100. 4.16. Cabozantinib - p. 225 101. 4.17. Capmatinib - p. 226 102. 4.18. Carfilzomib - p. 227 103. 4.19. Ceritinib - p. 229 104. 4.20. Cobimetinib - p. 230 105. 4.21. Copanlisib - p. 232 106. 4.22. Crizotinib - p. 233 107. 4.23. Dabrafenib - p. 234 108. 4.24. Dacomitinib - p. 236 109. 4.25. Dasatinib - p. 238 110. 4.26. Enasidenib - p. 241 111. 4.27. Encorafenib - p. 242 112. 4.28. Entrectinib - p. 244 113. 4.29. Erdafitinib - p. 245 114. 4.30. Erlotinib - p. 247 115. 4.31. Everolimus - p. 248 116. 4.32. Fedratinib - p. 250 117. 4.33. Fostamatinib - p. 252 118. 4.34. Gefitinib - p. 253 119. 4.35. Gilteritinib - p. 254 120. 4.36. Glasdegib - p. 256 121. 4.37. Ibrutinib - p. 257 122. 4.38. Idelalisib - p. 259 123. 4.39. Imatinib - p. 260 124. 4.40. Imiquimod - p. 262 125. 4.41. Infigratinib - p. 264 126. 4.42. Iobenguane I 131 - p. 265 127. 4.43. Ivosidenib - p. 266 128. 4.44. Ixazomib - p. 268 129. 4.45. Lapatinib - p. 269 130. 4.46. Larotrectinib - p. 271 131. 4.47. Lenalidomide - p. 272 132. 4.48. Lenvatinib - p. 274 133. 4.49. Lorlatinib - p. 276 134. 4.50. Midostaurin - p. 278 135. 4.51. Mobocertinib - p. 279 136. 4.52. Neratinib - p. 281 137. 4.53. Nilotinib - p. 282 138. 4.54. Niraparib - p. 284 139. 4.55. Olaparib - p. 285 140. 4.56. Omacetaxine mepesuccinate - p. 287 141. 4.57. Osimertinib - p. 289 142. 4.58. Palbociclib - p. 290 143. 4.59. Pazopanib - p. 292 144. 4.60. Pemigatinib - p. 293 145. 4.61. Pexidartinib - p. 295 146. 4.62. Pomalidomide - p. 296 147. 4.63. Ponatinib - p. 298 148. 4.64. Pralsetinib - p. 299 149. 4.65. Regorafenib - p. 301 150. 4.66. Ribociclib - p. 303 151. 4.67. Ripretinib - p. 304 152. 4.68. Romidepsin - p. 305 153. 4.69. Rucaparib - p. 307 154. 4.70. Selinexor - p. 308 155. 4.71. Selpercatinib - p. 310 156. 4.72. Selumetinib - p. 311 157. 4.73. Sonidegib - p. 313 158. 4.74. Sorafenib - p. 314 159. 4.75. Sunitinib - p. 315 160. 4.76. Talazoparib - p. 317 161. 4.77. Tazemetostat - p. 318 162. 4.78. Temsirolimus - p. 320 163. 4.79. Tepotinib - p. 321 164. 4.80. Thalidomide - p. 323 165. 4.81. Tivozanib - p. 324 166. 4.82. Trametinib - p. 325 167. 4.83. Tucatinib - p. 327 168. 4.84. Umbralisib - p. 329 169. 4.85. Vandetanib - p. 330 170. 4.86. Vemurafenib - p. 331 171. 4.87. Venetoclax - p. 333 172. 4.88. Vismodegib - p. 335 173. 4.89. Vorinostat - p. 336 174. 4.90. Zanubrutinib - p. 337 175. 4.91. Pharmacokinetics - p. 338 176. 4.92. Zoledronic acid - p. 338 177. Chapter 5. Targeted therapy: monoclonal antibody - p. 413 178. Chapter 6. Targeted therapy: antibody–drug conjugate - p. 459 179. Chapter 7. Immunotherapy - p. 489 180. Chapter 8. Drugs approved for different types of cancer - p. 541 181. Index - p. 575
Medicines for Cancer: Mechanism of Action and Clinical Pharmacology of Chemo, Hormonal, Targeted, and Immunotherapies covers most known anti-cancer therapeutics. Cancer is the second leading cause of death worldwide, with its various forms resulting in nearly one out of every six mortalities each year. This book describes all US FDA-approved drugs (up to 2021), such as small molecules, peptides, monoclonal antibodies, whole antibodies, gene therapy, antibody-drug conjugates, cell therapy, and immunotherapies, along with information on their generic and brand names, medical uses, details dosage, mechanisms of actions, pharmacokinetics and side effects. Chemical structures of small molecules, small peptides, antibody-drug conjugates are also provided.
This book is ideal for medicinal chemists, oncologists, and pharmacologists, but it will also be indispensable for professional researchers, whether they are working in the clinic or the pharmaceutical industry.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. Medical advice disclaimer - p. v 6. About the author - p. xvii 7. Preface - p. xix 8. Common abbreviations and acronyms - p. xxi 9. Chapter 1. Drug nomenclature - p. 1 10. Chapter 2. Chemotherapy - p. 7 11. 2.1. Alkylating antineoplastic agents - p. 7 12. 2.2. Nitrosoureas - p. 7 13. 2.3. Antimetabolites - p. 7 14. 2.4. Antitumor antibiotics - p. 8 15. 2.5. Topoisomerase inhibitors - p. 8 16. 2.6. Mitotic inhibitors (antimicrotubule agents) - p. 8 17. 2.7. Corticosteroids - p. 9 18. 2.8. Other chemotherapy drugs - p. 9 19. 2.9. US FDA-approved current chemotherapy agents - p. 9 20. 2.10. Albumin-bound paclitaxel - p. 9 21. 2.11. Amifostine - p. 11 22. 2.12. Arsenic trioxide - p. 12 23. 2.13. Asparaginase Erwinia chrysanthemi - p. 14 24. 2.14. Azacitidine - p. 15 25. 2.15. Bendamustine - p. 16 26. 2.16. Bleomycin - p. 18 27. 2.17. Busulfan - p. 19 28. 2.18. Cabazitaxel - p. 21 29. 2.19. Calaspargase pegol-mknl - p. 23 30. 2.20. Capecitabine - p. 24 31. 2.21. Carboplatin - p. 26 32. 2.22. Carmustine - p. 27 33. 2.23. Chlorambucil - p. 28 34. 2.24. Cisplatin - p. 30 35. 2.25. Cladribine - p. 31 36. 2.26. Clofarabine - p. 33 37. 2.27. Cyclophosphamide - p. 35 38. 2.28. Cytarabine - p. 36 39. 2.29. Dacarbazine - p. 38 40. 2.30. Dactinomycin - p. 39 41. 2.31. Daunorubicin - p. 41 42. 2.32. Decitabine - p. 42 43. 2.33. Dexamethasone - p. 44 44. 2.34. Docetaxel - p. 45 45. 2.35. Doxorubicin - p. 47 46. 2.36. Doxorubicin liposome - p. 49 47. 2.37. Epirubicin - p. 50 48. 2.38. Eribulin mesylate - p. 52 49. 2.39. Etoposide - p. 53 50. 2.40. Fludarabine - p. 55 51. 2.41. 5-Fluorouracil - p. 56 52. 2.42. Gemcitabine - p. 58 53. 2.43. Hydroxyurea - p. 61 54. 2.44. Idarubicin - p. 62 55. 2.45. Ifosfamide - p. 64 56. 2.46. Irinotecan - p. 66 57. 2.47. Ixabepilone - p. 68 58. 2.48. Lomustine - p. 69 59. 2.49. Lurbinectedin - p. 70 60. 2.50. Lutetium Lu 177-dotatate - p. 72 61. 2.51. Mechlorethamine - p. 73 62. 2.52. Melphalan - p. 74 63. 2.53. Mercaptopurine - p. 76 64. 2.54. Methotrexate - p. 77 65. 2.55. Mitomycin-C - p. 79 66. 2.56. Mitoxantrone - p. 80 67. 2.57. Nelarabine - p. 82 68. 2.58. Oxaliplatin - p. 83 69. 2.59. Paclitaxel - p. 85 70. 2.60. Pemetrexed - p. 87 71. 2.61. Pralatrexate - p. 89 72. 2.62. Procarbazine - p. 90 73. 2.63. Radium 223 dichloride - p. 92 74. 2.64. Temozolomide - p. 93 75. 2.65. Thioguanine - p. 94 76. 2.66. Thiotepa - p. 96 77. 2.67. Topotecan - p. 97 78. 2.68. Trabectedin - p. 99 79. 2.69. Valrubicin - p. 100 80. 2.70. Vinblastine - p. 102 81. 2.71. Vincristine - p. 103 82. 2.72. Vinorelbine - p. 105 83. Chapter 3. Hormonal therapy - p. 161 84. Chapter 4. Targeted therapy: small molecules - p. 205 85. 4.1. Small molecules - p. 205 86. 4.2. Small molecules as targeted therapy - p. 205 87. 4.3. Abemaciclib - p. 205 88. 4.4. Acalabrutinib - p. 207 89. 4.5. Afatinib - p. 208 90. 4.6. Alectinib - p. 210 91. 4.7. Alpelisib - p. 211 92. 4.8. Avapritinib - p. 212 93. 4.9. Axitinib - p. 214 94. 4.10. Belinostat - p. 216 95. 4.11. Bexarotene - p. 217 96. 4.12. Binimetinib - p. 218 97. 4.13. Bortezomib - p. 220 98. 4.14. Bosutinib - p. 222 99. 4.15. Brigatinib - p. 223 100. 4.16. Cabozantinib - p. 225 101. 4.17. Capmatinib - p. 226 102. 4.18. Carfilzomib - p. 227 103. 4.19. Ceritinib - p. 229 104. 4.20. Cobimetinib - p. 230 105. 4.21. Copanlisib - p. 232 106. 4.22. Crizotinib - p. 233 107. 4.23. Dabrafenib - p. 234 108. 4.24. Dacomitinib - p. 236 109. 4.25. Dasatinib - p. 238 110. 4.26. Enasidenib - p. 241 111. 4.27. Encorafenib - p. 242 112. 4.28. Entrectinib - p. 244 113. 4.29. Erdafitinib - p. 245 114. 4.30. Erlotinib - p. 247 115. 4.31. Everolimus - p. 248 116. 4.32. Fedratinib - p. 250 117. 4.33. Fostamatinib - p. 252 118. 4.34. Gefitinib - p. 253 119. 4.35. Gilteritinib - p. 254 120. 4.36. Glasdegib - p. 256 121. 4.37. Ibrutinib - p. 257 122. 4.38. Idelalisib - p. 259 123. 4.39. Imatinib - p. 260 124. 4.40. Imiquimod - p. 262 125. 4.41. Infigratinib - p. 264 126. 4.42. Iobenguane I 131 - p. 265 127. 4.43. Ivosidenib - p. 266 128. 4.44. Ixazomib - p. 268 129. 4.45. Lapatinib - p. 269 130. 4.46. Larotrectinib - p. 271 131. 4.47. Lenalidomide - p. 272 132. 4.48. Lenvatinib - p. 274 133. 4.49. Lorlatinib - p. 276 134. 4.50. Midostaurin - p. 278 135. 4.51. Mobocertinib - p. 279 136. 4.52. Neratinib - p. 281 137. 4.53. Nilotinib - p. 282 138. 4.54. Niraparib - p. 284 139. 4.55. Olaparib - p. 285 140. 4.56. Omacetaxine mepesuccinate - p. 287 141. 4.57. Osimertinib - p. 289 142. 4.58. Palbociclib - p. 290 143. 4.59. Pazopanib - p. 292 144. 4.60. Pemigatinib - p. 293 145. 4.61. Pexidartinib - p. 295 146. 4.62. Pomalidomide - p. 296 147. 4.63. Ponatinib - p. 298 148. 4.64. Pralsetinib - p. 299 149. 4.65. Regorafenib - p. 301 150. 4.66. Ribociclib - p. 303 151. 4.67. Ripretinib - p. 304 152. 4.68. Romidepsin - p. 305 153. 4.69. Rucaparib - p. 307 154. 4.70. Selinexor - p. 308 155. 4.71. Selpercatinib - p. 310 156. 4.72. Selumetinib - p. 311 157. 4.73. Sonidegib - p. 313 158. 4.74. Sorafenib - p. 314 159. 4.75. Sunitinib - p. 315 160. 4.76. Talazoparib - p. 317 161. 4.77. Tazemetostat - p. 318 162. 4.78. Temsirolimus - p. 320 163. 4.79. Tepotinib - p. 321 164. 4.80. Thalidomide - p. 323 165. 4.81. Tivozanib - p. 324 166. 4.82. Trametinib - p. 325 167. 4.83. Tucatinib - p. 327 168. 4.84. Umbralisib - p. 329 169. 4.85. Vandetanib - p. 330 170. 4.86. Vemurafenib - p. 331 171. 4.87. Venetoclax - p. 333 172. 4.88. Vismodegib - p. 335 173. 4.89. Vorinostat - p. 336 174. 4.90. Zanubrutinib - p. 337 175. 4.91. Pharmacokinetics - p. 338 176. 4.92. Zoledronic acid - p. 338 177. Chapter 5. Targeted therapy: monoclonal antibody - p. 413 178. Chapter 6. Targeted therapy: antibody–drug conjugate - p. 459 179. Chapter 7. Immunotherapy - p. 489 180. Chapter 8. Drugs approved for different types of cancer - p. 541 181. Index - p. 575
